Key statistics dashboard for Kairos Pharma, Ltd. (KAPA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd.
Stock Data
| Price | $1.81 |
| Market Cap | $6M |
| Beta | 1.98 |
| Exchange | AMEX |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.94 |
| Price / Book | 1.33 |
| P/S | 0.00 |
| P/FCF | -1.40 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 11.98 |
| Quick Ratio | 11.98 |
| Cash Ratio | 9.91 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 1.37 |
| Cash per share | 0.86 |
| FCF per share | -1.30 |
| Tangible Book Value per share | 1.37 |
| Dividend per share | 0.00 |
Explore sector: Healthcare · Biotechnology
More sections of KAPA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks